 | • レポートコード：MRC23Q36200 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のナノ粒子媒介送達市場について調査・分析し、世界のナノ粒子媒介送達市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（生物由来、非生物由来）、用途別セグメント分析（ドラッグデリバリー、遺伝子デリバリー）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、AbbVie、BlueWillow Biologics、NovaSOL、Camurus、Ceramisphere、Celgene, CytImmune、Cristal Therapeutics、EnColl、Lena Nanoceutics Ltd.、EyePoint Pharmaceuticals、Nanobiotix、NanoCarrier、Nanospectra、NanOlogy、Selecta Biosciences、Parvus Therapeutics、Starpharma、Tarveda Therapeuticsなどが含まれています。 世界のナノ粒子媒介送達市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ナノ粒子媒介送達市場規模を推定する際に考慮しました。本レポートは、ナノ粒子媒介送達の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ナノ粒子媒介送達に関するビジネス上の意思決定に役立てることを目的としています。 ・ナノ粒子媒介送達市場の概要 - ナノ粒子媒介送達のタイプ別セグメント - 世界のナノ粒子媒介送達市場規模：タイプ別分析（生物由来、非生物由来） - ナノ粒子媒介送達の用途別セグメント - 世界のナノ粒子媒介送達市場規模：用途別分析（ドラッグデリバリー、遺伝子デリバリー） - 世界のナノ粒子媒介送達市場規模予測（2018年-2029年） ・ナノ粒子媒介送達市場の成長トレンド - ナノ粒子媒介送達の地域別市場規模（2018年-2029年） - ナノ粒子媒介送達市場ダイナミクス - ナノ粒子媒介送達の業界動向 - ナノ粒子媒介送達市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：生物由来、非生物由来 - 世界のナノ粒子媒介送達のタイプ別市場規模（2018年-2023年） - 世界のナノ粒子媒介送達のタイプ別市場規模（2024年-2029年） ・用途別セグメント：ドラッグデリバリー、遺伝子デリバリー - 世界のナノ粒子媒介送達の用途別市場規模（2018年-2023年） - 世界のナノ粒子媒介送達の用途別市場規模（2024年-2029年） ・ナノ粒子媒介送達の地域別市場規模 - 北米のナノ粒子媒介送達市場規模（2018年-2029年） - アメリカのナノ粒子媒介送達市場規模（2018年-2029年） - ヨーロッパのナノ粒子媒介送達市場規模（2018年-2029年） - アジア太平洋のナノ粒子媒介送達市場規模（2018年-2029年） - 中国のナノ粒子媒介送達市場規模（2018年-2029年） - 日本のナノ粒子媒介送達市場規模（2018年-2029年） - 韓国のナノ粒子媒介送達市場規模（2018年-2029年） - インドのナノ粒子媒介送達市場規模（2018年-2029年） - オーストラリアのナノ粒子媒介送達市場規模（2018年-2029年） - 中南米のナノ粒子媒介送達市場規模（2018年-2029年） - 中東・アフリカのナノ粒子媒介送達市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 AbbVie、BlueWillow Biologics、NovaSOL、Camurus、Ceramisphere、Celgene, CytImmune、Cristal Therapeutics、EnColl、Lena Nanoceutics Ltd.、EyePoint Pharmaceuticals、Nanobiotix、NanoCarrier、Nanospectra、NanOlogy、Selecta Biosciences、Parvus Therapeutics、Starpharma、Tarveda Therapeutics ・アナリストの観点/結論 ・調査方法とデータソース |
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
In this report, we only study liposomal/lipid nanoparticle drug delivery system.
LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).
In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.
Highlights
The global Nanoparticle-Mediated Delivery market was valued at US$ 4766.2 million in 2022 and is anticipated to reach US$ 5927.2 million by 2029, witnessing a CAGR of 3.7% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Nanoparticle Drug Delivery Systems key players include Gilead Sciences, CSPC, Pacira, Alnylam, etc. Global top four manufacturers hold a share about 37%.
Asia-Pacific is the largest market, with a share about 37%, followed by Europe, and North America, both have a share over 56 percent.
In terms of product, Liposomes Drugs is the largest segment, with a share over 92%. And in terms of application, the largest application is Retail Pharmacy, followed by Hospital, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nanoparticle-Mediated Delivery, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nanoparticle-Mediated Delivery.
The Nanoparticle-Mediated Delivery market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Nanoparticle-Mediated Delivery market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nanoparticle-Mediated Delivery companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
AbbVie
BlueWillow Biologics
NovaSOL
Camurus
Ceramisphere
Celgene, CytImmune
Cristal Therapeutics
EnColl
Lena Nanoceutics Ltd.
EyePoint Pharmaceuticals
Nanobiotix
NanoCarrier
Nanospectra
NanOlogy
Selecta Biosciences
Parvus Therapeutics
Starpharma
Tarveda Therapeutics
Segment by Type
Biological Origin
Non-Biological Origin
Segment by Application
Drug Delivery
Gene Delivery
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nanoparticle-Mediated Delivery companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nanoparticle-Mediated Delivery Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Biological Origin
1.2.3 Non-Biological Origin
1.3 Market by Application
1.3.1 Global Nanoparticle-Mediated Delivery Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Drug Delivery
1.3.3 Gene Delivery
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nanoparticle-Mediated Delivery Market Perspective (2018-2029)
2.2 Nanoparticle-Mediated Delivery Growth Trends by Region
2.2.1 Global Nanoparticle-Mediated Delivery Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nanoparticle-Mediated Delivery Historic Market Size by Region (2018-2023)
2.2.3 Nanoparticle-Mediated Delivery Forecasted Market Size by Region (2024-2029)
2.3 Nanoparticle-Mediated Delivery Market Dynamics
2.3.1 Nanoparticle-Mediated Delivery Industry Trends
2.3.2 Nanoparticle-Mediated Delivery Market Drivers
2.3.3 Nanoparticle-Mediated Delivery Market Challenges
2.3.4 Nanoparticle-Mediated Delivery Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nanoparticle-Mediated Delivery Players by Revenue
3.1.1 Global Top Nanoparticle-Mediated Delivery Players by Revenue (2018-2023)
3.1.2 Global Nanoparticle-Mediated Delivery Revenue Market Share by Players (2018-2023)
3.2 Global Nanoparticle-Mediated Delivery Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nanoparticle-Mediated Delivery Revenue
3.4 Global Nanoparticle-Mediated Delivery Market Concentration Ratio
3.4.1 Global Nanoparticle-Mediated Delivery Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nanoparticle-Mediated Delivery Revenue in 2022
3.5 Nanoparticle-Mediated Delivery Key Players Head office and Area Served
3.6 Key Players Nanoparticle-Mediated Delivery Product Solution and Service
3.7 Date of Enter into Nanoparticle-Mediated Delivery Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nanoparticle-Mediated Delivery Breakdown Data by Type
4.1 Global Nanoparticle-Mediated Delivery Historic Market Size by Type (2018-2023)
4.2 Global Nanoparticle-Mediated Delivery Forecasted Market Size by Type (2024-2029)
5 Nanoparticle-Mediated Delivery Breakdown Data by Application
5.1 Global Nanoparticle-Mediated Delivery Historic Market Size by Application (2018-2023)
5.2 Global Nanoparticle-Mediated Delivery Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Nanoparticle-Mediated Delivery Market Size (2018-2029)
6.2 North America Nanoparticle-Mediated Delivery Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nanoparticle-Mediated Delivery Market Size by Country (2018-2023)
6.4 North America Nanoparticle-Mediated Delivery Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nanoparticle-Mediated Delivery Market Size (2018-2029)
7.2 Europe Nanoparticle-Mediated Delivery Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nanoparticle-Mediated Delivery Market Size by Country (2018-2023)
7.4 Europe Nanoparticle-Mediated Delivery Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nanoparticle-Mediated Delivery Market Size (2018-2029)
8.2 Asia-Pacific Nanoparticle-Mediated Delivery Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nanoparticle-Mediated Delivery Market Size by Region (2018-2023)
8.4 Asia-Pacific Nanoparticle-Mediated Delivery Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nanoparticle-Mediated Delivery Market Size (2018-2029)
9.2 Latin America Nanoparticle-Mediated Delivery Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nanoparticle-Mediated Delivery Market Size by Country (2018-2023)
9.4 Latin America Nanoparticle-Mediated Delivery Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nanoparticle-Mediated Delivery Market Size (2018-2029)
10.2 Middle East & Africa Nanoparticle-Mediated Delivery Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nanoparticle-Mediated Delivery Market Size by Country (2018-2023)
10.4 Middle East & Africa Nanoparticle-Mediated Delivery Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Nanoparticle-Mediated Delivery Introduction
11.1.4 AbbVie Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.1.5 AbbVie Recent Development
11.2 BlueWillow Biologics
11.2.1 BlueWillow Biologics Company Detail
11.2.2 BlueWillow Biologics Business Overview
11.2.3 BlueWillow Biologics Nanoparticle-Mediated Delivery Introduction
11.2.4 BlueWillow Biologics Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.2.5 BlueWillow Biologics Recent Development
11.3 NovaSOL
11.3.1 NovaSOL Company Detail
11.3.2 NovaSOL Business Overview
11.3.3 NovaSOL Nanoparticle-Mediated Delivery Introduction
11.3.4 NovaSOL Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.3.5 NovaSOL Recent Development
11.4 Camurus
11.4.1 Camurus Company Detail
11.4.2 Camurus Business Overview
11.4.3 Camurus Nanoparticle-Mediated Delivery Introduction
11.4.4 Camurus Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.4.5 Camurus Recent Development
11.5 Ceramisphere
11.5.1 Ceramisphere Company Detail
11.5.2 Ceramisphere Business Overview
11.5.3 Ceramisphere Nanoparticle-Mediated Delivery Introduction
11.5.4 Ceramisphere Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.5.5 Ceramisphere Recent Development
11.6 Celgene, CytImmune
11.6.1 Celgene, CytImmune Company Detail
11.6.2 Celgene, CytImmune Business Overview
11.6.3 Celgene, CytImmune Nanoparticle-Mediated Delivery Introduction
11.6.4 Celgene, CytImmune Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.6.5 Celgene, CytImmune Recent Development
11.7 Cristal Therapeutics
11.7.1 Cristal Therapeutics Company Detail
11.7.2 Cristal Therapeutics Business Overview
11.7.3 Cristal Therapeutics Nanoparticle-Mediated Delivery Introduction
11.7.4 Cristal Therapeutics Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.7.5 Cristal Therapeutics Recent Development
11.8 EnColl
11.8.1 EnColl Company Detail
11.8.2 EnColl Business Overview
11.8.3 EnColl Nanoparticle-Mediated Delivery Introduction
11.8.4 EnColl Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.8.5 EnColl Recent Development
11.9 Lena Nanoceutics Ltd.
11.9.1 Lena Nanoceutics Ltd. Company Detail
11.9.2 Lena Nanoceutics Ltd. Business Overview
11.9.3 Lena Nanoceutics Ltd. Nanoparticle-Mediated Delivery Introduction
11.9.4 Lena Nanoceutics Ltd. Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.9.5 Lena Nanoceutics Ltd. Recent Development
11.10 EyePoint Pharmaceuticals
11.10.1 EyePoint Pharmaceuticals Company Detail
11.10.2 EyePoint Pharmaceuticals Business Overview
11.10.3 EyePoint Pharmaceuticals Nanoparticle-Mediated Delivery Introduction
11.10.4 EyePoint Pharmaceuticals Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.10.5 EyePoint Pharmaceuticals Recent Development
11.11 Nanobiotix
11.11.1 Nanobiotix Company Detail
11.11.2 Nanobiotix Business Overview
11.11.3 Nanobiotix Nanoparticle-Mediated Delivery Introduction
11.11.4 Nanobiotix Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.11.5 Nanobiotix Recent Development
11.12 NanoCarrier
11.12.1 NanoCarrier Company Detail
11.12.2 NanoCarrier Business Overview
11.12.3 NanoCarrier Nanoparticle-Mediated Delivery Introduction
11.12.4 NanoCarrier Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.12.5 NanoCarrier Recent Development
11.13 Nanospectra
11.13.1 Nanospectra Company Detail
11.13.2 Nanospectra Business Overview
11.13.3 Nanospectra Nanoparticle-Mediated Delivery Introduction
11.13.4 Nanospectra Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.13.5 Nanospectra Recent Development
11.14 NanOlogy
11.14.1 NanOlogy Company Detail
11.14.2 NanOlogy Business Overview
11.14.3 NanOlogy Nanoparticle-Mediated Delivery Introduction
11.14.4 NanOlogy Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.14.5 NanOlogy Recent Development
11.15 Selecta Biosciences
11.15.1 Selecta Biosciences Company Detail
11.15.2 Selecta Biosciences Business Overview
11.15.3 Selecta Biosciences Nanoparticle-Mediated Delivery Introduction
11.15.4 Selecta Biosciences Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.15.5 Selecta Biosciences Recent Development
11.16 Parvus Therapeutics
11.16.1 Parvus Therapeutics Company Detail
11.16.2 Parvus Therapeutics Business Overview
11.16.3 Parvus Therapeutics Nanoparticle-Mediated Delivery Introduction
11.16.4 Parvus Therapeutics Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.16.5 Parvus Therapeutics Recent Development
11.17 Starpharma
11.17.1 Starpharma Company Detail
11.17.2 Starpharma Business Overview
11.17.3 Starpharma Nanoparticle-Mediated Delivery Introduction
11.17.4 Starpharma Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.17.5 Starpharma Recent Development
11.18 Tarveda Therapeutics
11.18.1 Tarveda Therapeutics Company Detail
11.18.2 Tarveda Therapeutics Business Overview
11.18.3 Tarveda Therapeutics Nanoparticle-Mediated Delivery Introduction
11.18.4 Tarveda Therapeutics Revenue in Nanoparticle-Mediated Delivery Business (2018-2023)
11.18.5 Tarveda Therapeutics Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details